Navigation Links
Starving cancer cells of cholesterol might offer a new way to treat brain tumors
Date:9/15/2011

COLUMBUS, Ohio A new study suggests that blocking cancer cells' access to cholesterol may offer a new strategy for treating glioblastoma, the most common and deadly form of brain cancer, and perhaps other malignancies. The potential treatment could be appropriate for tumors with a hyperactive PI3K signaling pathway, which accounts for up to 90 percent of glioblastomas cases.

Researchers at the Ohio State University Comprehensive Cancer Center Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC James) and at UCLA's Jonsson Comprehensive Cancer Center who led the study discovered that the hyperactive signaling pathway is linked to cholesterol metabolism, and that inhibiting this pathway leads to the death of glioblastoma cells in an animal model.

he findings are published in the journal Cancer Discovery.

"Our research shows that the tumor cells depend on large amounts of cholesterol for growth and survival, and that pharmacologically depriving tumor cells of cholesterol may offer a novel therapeutic strategy to treat glioblastoma," says first author and researcher Dr. Deliang Guo, assistant professor of radiation oncology at the OSUCCC James.

"This study uncovers a mechanism that links a common oncogene with altered cell metabolism, and it potentially offers a strategy for blocking that mechanism and causing specific tumor-cell death without significant toxicity," says principal investigator Dr. Paul S. Mischel, professor of pathology at UCLA's Jonsson Cancer Center and an adjunct professor of radiation oncology at the OSUCCC James.

"Overall, our findings suggest that the development of drugs to target this pathway may lead to significantly more effective treatments for patients with this lethal form of brain cancer."

Glioblastomas strike about 18,500 Americans annually and kill nearly 13,000 of them. Glioblastoma multiforme is the most common and lethal form of the malignancy, with an average survival of 15 months after diagnosis. The tumors are difficult to surgically remove because malignant cells invade surrounding brain tissue.

In addition, genetic differences leave some glioblastoma cells in the tumor resistant to chemo- and radiation therapy, the researchers say.

"Some glioblastomas respond well to treatment initially when the therapy-sensitive cells are killed, but the tumor then returns relatively quickly as the therapy-resistant cells proliferate," says co-author Dr. Arnab Chakravarti, chair and professor of Radiation Oncology and co-director of the OSUCCC James Brain Tumor Program.

"Because glioblastomas are among the most treatment-resistant of cancers, new therapeutic strategies are urgently needed," says Chakravarti.

The study used tumor-cell lines, cells from patients and an animal model. Key technical findings include the following:

  • In nearly 50 percent of glioblastomas, a mutation called EGFRvIII hyperactivates the PI3K signaling pathway and a master transcriptional regulator called SREBP-1.

  • Activating this pathway upregulates the low-density lipoprotein (LDL) receptor and promotes LDL uptake, enabling tumor cells to import large amounts of cholesterol that feed tumor-cell growth and survival.

  • Pharmacological activation of the nuclear Liver X Receptor leads to the loss of LDL receptors and to upregulation of the ABCA1 protein pump, which transports cholesterol out of the malignant cells. Together, these actions starve tumor cells of cholesterol, causing their death.

"Because this pathway is activated in other types of cancer, this work may have significant implications for a broad range of cancer types," Mischel says.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Starving inflammatory immune cells slows damage caused by multiple sclerosis
2. Enhancing arrest of cell growth to treat cancer in mice
3. Paxil Blocks Tamoxifen, Lowers Survival Odds Against Breast Cancer
4. The National Coalition for Cancer Survivorship Joins the Commission on Cancer
5. Low forms of cyclin E reduce breast cancer drugs effectiveness
6. Racial disparities persist in the diagnosis of advanced breast cancer and colon cancer in the U.S.
7. Soft drinks may increase risk of pancreatic cancer
8. UH Case Medical Center researchers publish promising findings for advanced cervical cancer
9. Genes Play Role in Prognosis With Non-Small Cell Lung Cancers
10. Single gene mutation induces endometrial cancer
11. Certain genetic profiles associated with recurrence-free survival for non-small cell lung cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2017)... CA (PRWEB) , ... June 25, 2017 , ... FCPX ... media into an old-fashioned vintage look. FCPX LUT Vintage Volume 2 contains 60 different ... film grain for distorted looks, vignettes and blurs to single out subjects, plus much ...
(Date:6/25/2017)... ... ... Republicans in the United States Senate on Thursday released their version of bill ... significantly from the American Health Care Act, which the House passed in May, so ... have to take up the Senate version as-is, if it passes. , The following ...
(Date:6/25/2017)... ... June 25, 2017 , ... CareSet Labs released the Root NPI Graph today ... a new, greatly improved version of the Doctor Referral teaming dataset commonly available from ... and subsequently called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” ...
(Date:6/25/2017)... ... ... Men’s Health Month and the focus is on prostate cancer. Second only to skin ... third most common cause of cancer related death today; lung cancer remains in the number ... prostate cancer during his lifetime. Those at highest risk are men who have ...
(Date:6/24/2017)... ... June 24, 2017 , ... ... at the Sheraton Erie Bayfront and Erie Convention Center on June 8-10. ... exhibits, a student quiz bowl, award and scholarship presentations, and professional networking. ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... 25, 2017  In response to the opioid epidemic ... Relief is working with Pfizer to make up to ... cost to community health centers, free and charitable clinics, ... "Pfizer has a long-standing commitment to improving ... patient safety through educational activities," said Caroline Roan ...
(Date:5/22/2017)... , May 22, 2017  Lilac Corp, ... Gene-Eden-VIR/Novirin, announces the launch of a new ... the results of a clinical study that showed ... treatment with Gene-Eden-VIR/Novirin in individuals suffering from HPV ... note that there are no other treatments that ...
(Date:5/18/2017)... 2017  Bayer announced today that the latest research ... at the 53 rd Annual Meeting of the ... 2-6 in Chicago . ... colorectal, liver and thyroid cancers, as well as lymphomas, ... CHRONOS-1 trial of copanlisib in patients with relapsed or ...
Breaking Medicine Technology: